Clinical trials: BLADDER AND BOWEL DYSFUNCTION
Breast Cancer, Colorectal Cancer
A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT00709462
- Testing
- CDX1307
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celldex Therapeutics
Non-small Cell Lung Carcinoma (NSCLC), Melanoma
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
The purpose of this study is to evaluate the safety and tolerability of humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 (CM-24 [MK-6018]), administered intravenously as monotherapy and in combination with…
- Conditions
- Non-small Cell Lung Carcinoma (NSCLC), Melanoma, Bladder Cancer, Colorectal Cancer
- Trial name
- NCT02346955
- Testing
- CM-24 (MK-6018), Pembrolizumab (MK-3475)
- Where
- 3 sites in United States, Israel
- Volunteers
- 27 people
- Sponsor
- Famewave Ltd.
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Locally Advanced Solid Tumor, Metastatic Cancer
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer
- Trial name
- NCT04319757
- Testing
- ACE1702, Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 12 people
- Sponsor
- Acepodia Biotech, Inc.
Solid Tumor Malignancies, Colorectal Carcinoma
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383.
- Conditions
- Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC)
- Trial name
- NCT07030257
- Testing
- CP-383
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Tasca Therapeutics
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
- Trial name
- NCT07335484
- Testing
- Axonics External Trial System (ETS)
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- Axonics, Inc.
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics
Pelvic Organ Prolapse
Restorelle® Mesh Versus Native Tissue Repair for Prolapse
The purpose of this study is to collect information on the safety and effectiveness of Restorelle Direct Fix mesh and the surgical procedure to implant Restorelle.
- Trial name
- NCT02162615
- Testing
- Restorelle Direct Fix A, Restorelle Direct Fix P, Native Tissue Repair Anterior
- Where
- 49 sites in United States, Australia and 4 more
- Volunteers
- 810 people
- Sponsor
- Coloplast A/S
Non-Small Cell Lung Carcinoma, Breast Cancer
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.
- Conditions
- Non-Small Cell Lung Carcinoma, Breast Cancer, Melanoma, Upper GI Tract Carcinoma
- Trial name
- NCT00753415
- Testing
- V935, V934-EP
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Incontinence, Fecal Incontinence
Safety and Performance of UCon for the Treatment of the Symptoms of Overactive Bladder (OAB) / Bowel Dysfunction (BD)
This clinical investigation is a single-arm, prospective, multicentre, early feasibility study, which is used to evaluate the device design of UCon with respect to initial clinical safety and device performance in a small number…
- Conditions
- Urinary Incontinence, Fecal Incontinence, Urge Incontinence, Nocturia
- Trial name
- NCT05368246
- Testing
- UCon
- Where
- 3 sites in Denmark
- Volunteers
- 80 people
- Sponsor
- InnoCon Medical
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
This study is being done to find out the side effects (unwanted effects) that are caused in patients with cancers who are given SGN-2FF.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Breast Neoplasms, Urinary Bladder Neoplasm
- Trial name
- NCT02952989
- Testing
- SGN-2FF, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- Seagen Inc.
Neoplasms, Breast, Neoplasms, Lung
Study of ESG401 in Adults With Solid Tumors
The primary objective in Phase I is to evaluate the safety and tolerability of ESG401 as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial cancer.
- Conditions
- Neoplasms, Breast, Neoplasms, Lung, Neoplasms,Colorectal, Neoplasms, Bladder
- Trial name
- NCT04892342
- Testing
- ESG401
- Where
- 3 sites in China
- Volunteers
- 156 people
- Sponsor
- Shanghai Escugen Biotechnology Co., Ltd
Advanced Solid Tumor, Metastatic Cancer
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
The purpose of the Phase 1/2a study is to evaluate the safety and tolerability of SNK01 in combination with trastuzumab or cetuximab in order to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), and the…
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer, HER2-positive Gastric Cancer
- Trial name
- NCT04464967
- Testing
- SNK01, Trastuzumab, Cetuximab
- Sponsor
- NKGen Biotech, Inc.
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Overactive Bladder, Fecal Incontinence
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
To collect physiological signals at several timepoints during the therapy evaluation period.
- Conditions
- Overactive Bladder, Fecal Incontinence, Urinary Retention
- Trial name
- PEER 2 (NCT05200923)
- Testing
- Sacral Neuromodulation
- Where
- 7 sites in United States
- Volunteers
- 300 people
- Sponsor
- MedtronicNeuro
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination
The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer
- Trial name
- LTbR (NCT06448364)
- Testing
- PF-07329640, sasanlimab, bevacizumab
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- Pfizer
Overactive Bladder, Fecal Incontinence
InterStim Micro Post Market Clinical Follow-up Study (ELITE)
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
- Conditions
- Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
- Trial name
- ELITE (NCT04506866)
- Testing
- InterStim Micro
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 148 people
- Sponsor
- MedtronicNeuro
Cancer of Pancreas, Cancer of Liver
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
A Randomized, Double-Blind, Placebo-Controlled, Parallel, Multi-Center Study to Assess the Efficacy of BRCX014 Combined with Standard-Of-Care Treatment in Subjects with Glioblastoma Multiforme, Multiple Myeloma, and GI…
- Conditions
- Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon
- Trial name
- NCT03607643
- Testing
- Cannabidiol, Bortezomib, Leucovorin
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Leaf Vertical Inc.